City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
City of Hope’s commitment to Diversity, Equity and Inclusion
We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
The Williams lab is looking for a highly motivated postdoctoral student interested in working in translational medicine to treat cancer. The overarching goals of the group are to identify and address unmet clinical needs (e.g., on-target, off-tissue toxicities) by rapidly translating novel molecular designs to the clinic. Using an atoms-up approach, our group pioneered the concept and development of tumor-activated IO monoclonal antibodies, leading the formation of Xilio Therapeutics which has two products currently in phase 1/2 clinical trials. We also discovered and subsequently developed a unique peptide-Fab interaction that allows us to rapidly functionalize monoclonal antibodies including antibody-drug conjugates, bispecifics including NK and T cell engagers, antibody-based imaging reagents, and switchable CAR T cells. Given these successes, we have broadly expanded our efforts including the discovery of novel antibodies, combining single cell techniques (enabled by the acquisition of a Berkeley Lights Beacon) with structural and computational biology efforts.
We widely collaborate with clinicians at City of Hope and leverage the outstanding share resources including three FDA-approved GMP facilities (supported in part by the NCI-designated Comprehensive Cancer Center) to ensure we are creating clinically viable leads. Given the wealth of these resources, we have a large number of very exciting existing projects that require additional efforts before entering the clinic as well as multiple ‘on-the-drawing’ board concepts that we intend to advance.
Basic education, experience and skills required for consideration:
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.